EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

The impact of cholinesterase inhibitors on cognitive trajectories in mild cognitive impairment patients based on amyloid beta status

Wenying Liu, Yan Li, Wei Qin, Xuechu Wang, Wenwen Li, Ying Li, Alzheimer's Disease Neuroimaging Initiative, Jianping Jia iD

Alzheimer's & Dementia · 2025-05 · 21 (5)

DOI: 10.1002/alz.70193 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 15.05.2025. Verfasst von Wenying Liu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Innovation Center for Neurological Disorders and Department of Neurology, National Clinical Research Center for Geriatric Diseases, Xuanwu Hospital, …. Hauptthemen laut MEDLINE: Cognitive Dysfunction, Cholinesterase Inhibitors, Amyloid beta-Peptides, Alzheimer Disease. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Beijing Municipal Natural Science Foundation, Chinese Institutes for Medical Research, NIA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION This study examines whether cholinesterase inhibitors (ChEIs) influence the progression to Alzheimer's disease (AD) dementia and cognitive trajectories in amnestic mild cognitive impairment (MCI) patients, considering their amyloid beta (Aβ) status. METHODS Kaplan–Meier and time‐varying Cox models evaluated ChEI use and different Aβ status on MCI‐to‐AD progression. Linear mixed‐effects models assessed cognitive trajectories. Locally estimated scatterplot smoothing regression analyzed cognitive changes before and after ChEI initiation. RESULTS Among 558 amnestic MCI participants (168 ChEI users), ChEI users exhibited higher risk of progression to AD dementia (hazard ratio = 1.77, 95% confidence interval: 1.15 to 2.73, p = 0.001). Both ChEI use and Aβ burden independently accelerated MCI progression and cognitive decline. Cognitive trajectories demonstrated decline before ChEI initiation and continued to decline after treatment began. DISCUSSION The association between ChEI treatment and accelerated progression to AD dementia and cognitive decline, independent of Aβ status, emphasized the need to reconsider optimal timing for ChEI initiation in MCI. Highlights ChEI use in MCI was associated with increased risk of progression to AD dementia. ChEI use in MCI was associated with accelerated longitudinal cognitive decline. Cognitive decline persisted after ChEI initiation rather than reversing. ChEI effects on MCI progression to AD dementia were independent of Aβ status.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cognitive DysfunctionCholinesterase InhibitorsAmyloid beta-PeptidesAlzheimer DiseaseCognitionHumansMaleFemaleDisease ProgressionAgedNeuropsychological TestsAged, 80 and overKaplan-Meier EstimateProportional Hazards Models

Stichwörter der Autor:innen

Alzheimer's disease dementiaamyloid betacholinesterase inhibitorsmild cognitive impairment

Substanzen

Cholinesterase InhibitorsAmyloid beta-Peptides

Autor:innen und Institutionen

  • Innovation Center for Neurological Disorders and Department of Neurology, National Clinical Research Center for Geriatric Diseases, Xuanwu Hospital, Capital Medical University, Beijing, P.R. China.
  • Beijing Key Laboratory of Geriatric Cognitive Disorders, Beijing, P.R. China.
  • Clinical Center for Neurodegenerative Disease and Memory Impairment, Capital Medical University, Beijing, P.R. China.
  • Center of Alzheimer's Disease, Beijing Institute of Brain Disorders, Collaborative Innovation Center for Brain Disorders, Capital Medical University, Beijing, P.R. China.
  • Key Laboratory of Neurodegenerative Diseases, Ministry of Education, Beijing, P.R. China.
  • The National Clinical Research Center for Mental Disorders & Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China.

ORCID-Profile: Jianping Jia

Förderung

  • Beijing Municipal Natural Science Foundation
  • Chinese Institutes for Medical Research
  • NIA NIH HHS
  • STI2030-Major Projects
  • National Natural Science Foundation of China
  • Key Project of the National Natural Science Foundation of China
  • National Key Scientific Instrument and Equipment Development Project
  • Beijing Brain Initiative from Beijing Municipal Science & Technology Commission

Zitieren

APA

Liu, W., Li, Y., Qin, W., Wang, X., Li, W., Li, Y., Alzheimer's Disease Neuroimaging Initiative, & Jia, J. (2025). The impact of cholinesterase inhibitors on cognitive trajectories in mild cognitive impairment patients based on amyloid beta status. Alzheimer's & Dementia, 21(5). https://doi.org/10.1002/alz.70193

Vancouver

Liu W, Li Y, Qin W, Wang X, Li W, Li Y, et al. The impact of cholinesterase inhibitors on cognitive trajectories in mild cognitive impairment patients based on amyloid beta status. Alzheimer's & Dementia. 2025;21(5). doi:10.1002/alz.70193

BibTeX
@article{Liu2025,
  author = {Liu, Wenying and Li, Yan and Qin, Wei and Wang, Xuechu and Li, Wenwen and Li, Ying and Alzheimer's Disease Neuroimaging Initiative, Alzheimer's Disease Neuroimaging Initiative and Jia, Jianping},
  title = {The impact of cholinesterase inhibitors on cognitive trajectories in mild cognitive impairment patients based on amyloid beta status},
  journal = {Alzheimer's & Dementia},
  year = {2025},
  volume = {21},
  number = {5},
  doi = {10.1002/alz.70193}
}
Kostenlos starten →